DE VITA, Salvatore
 Distribuzione geografica
Continente #
NA - Nord America 27.231
AS - Asia 12.982
EU - Europa 8.736
SA - Sud America 2.541
AF - Africa 288
Continente sconosciuto - Info sul continente non disponibili 29
OC - Oceania 18
AN - Antartide 2
Totale 51.827
Nazione #
US - Stati Uniti d'America 26.817
SG - Singapore 6.135
CN - Cina 2.626
UA - Ucraina 2.503
BR - Brasile 2.046
HK - Hong Kong 1.467
DE - Germania 1.337
IT - Italia 1.059
VN - Vietnam 1.033
FI - Finlandia 802
RU - Federazione Russa 625
FR - Francia 574
SE - Svezia 523
IE - Irlanda 479
GB - Regno Unito 376
IN - India 345
TR - Turchia 264
KR - Corea 261
CA - Canada 239
AR - Argentina 174
BD - Bangladesh 147
MX - Messico 104
EC - Ecuador 98
IQ - Iraq 95
ZA - Sudafrica 83
JP - Giappone 80
ID - Indonesia 79
NL - Olanda 71
AT - Austria 68
PL - Polonia 68
PK - Pakistan 61
CO - Colombia 51
MA - Marocco 51
IR - Iran 46
UZ - Uzbekistan 45
ES - Italia 44
CL - Cile 41
PY - Paraguay 40
SA - Arabia Saudita 40
PH - Filippine 39
VE - Venezuela 36
CZ - Repubblica Ceca 35
EG - Egitto 33
BE - Belgio 31
EU - Europa 27
TG - Togo 22
UY - Uruguay 22
TN - Tunisia 20
PE - Perù 19
AE - Emirati Arabi Uniti 18
MY - Malesia 18
DO - Repubblica Dominicana 16
IL - Israele 16
LT - Lituania 16
NP - Nepal 16
AZ - Azerbaigian 15
GR - Grecia 15
JO - Giordania 15
KE - Kenya 14
KZ - Kazakistan 14
PT - Portogallo 14
BO - Bolivia 13
LB - Libano 13
AU - Australia 12
CH - Svizzera 12
DZ - Algeria 12
JM - Giamaica 11
OM - Oman 11
AL - Albania 10
CR - Costa Rica 10
ET - Etiopia 10
RO - Romania 10
TW - Taiwan 10
HR - Croazia 9
KG - Kirghizistan 9
TT - Trinidad e Tobago 9
LK - Sri Lanka 8
PA - Panama 8
PS - Palestinian Territory 8
DK - Danimarca 7
NO - Norvegia 7
TH - Thailandia 7
HN - Honduras 6
HU - Ungheria 6
KW - Kuwait 6
NG - Nigeria 6
RS - Serbia 6
SN - Senegal 6
SY - Repubblica araba siriana 6
AM - Armenia 5
EE - Estonia 5
NZ - Nuova Zelanda 5
AO - Angola 4
BY - Bielorussia 4
GA - Gabon 4
GE - Georgia 4
LV - Lettonia 4
NI - Nicaragua 4
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
Totale 51.761
Città #
Woodbridge 3.780
Ann Arbor 2.593
Singapore 2.490
Fairfield 2.015
Houston 1.979
Jacksonville 1.764
Ashburn 1.721
Chandler 1.522
Hong Kong 1.440
Beijing 1.273
Wilmington 1.003
Dearborn 967
Seattle 714
Boardman 620
Cambridge 616
San Jose 485
Dublin 474
Lauterbourg 466
Princeton 466
Ho Chi Minh City 344
Los Angeles 339
Udine 305
Hefei 254
Seoul 239
Helsinki 227
Buffalo 217
Hanoi 209
Dallas 200
Munich 199
Izmir 191
San Diego 186
São Paulo 178
The Dalles 154
Redondo Beach 135
Ottawa 131
New York 130
Ogden 104
Des Moines 103
Council Bluffs 96
Norwalk 92
Santa Clara 82
Dong Ket 78
Mumbai 74
Nuremberg 66
Orem 63
Nanjing 60
Frankfurt am Main 58
Trieste 58
Belo Horizonte 55
Tokyo 55
Rio de Janeiro 54
Redmond 53
London 51
Guangzhou 50
Warsaw 46
Johannesburg 44
Milan 44
San Mateo 43
Kunming 42
Falls Church 41
Brooklyn 39
Montreal 39
Phoenix 39
Tashkent 39
Haiphong 37
Baghdad 36
Chennai 36
Guayaquil 36
Rome 36
Atlanta 35
Da Nang 35
Brasília 34
Denver 33
Quito 33
Toronto 33
Amsterdam 32
Salvador 32
Stockholm 32
Shanghai 31
Curitiba 30
Mexico City 29
Augusta 28
Brussels 28
Turku 28
Vienna 27
Brno 26
Chicago 26
Düsseldorf 26
Hải Dương 26
Campinas 25
Lahore 25
Manchester 25
Porto Alegre 25
Simi Valley 25
Andover 24
New Delhi 24
Lomé 22
Ribeirão Preto 22
Dhaka 21
Leawood 21
Totale 32.738
Nome #
Gastric B-cell clonal expansion and Helicobacter pylori infection in patients with autoimmune diseases and with dyspepsia. A follow-up study. 316
B-cell clonal expansion in gastric biopsies of patients with dyspepsia and autoimmune diseases: effect of H. Pylori eradication. 196
Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. 195
A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: A nationwide multi-center retrospective observational study 192
Absence of human parvovirus B19 DNA in myoepithelial sialadenitis of primary Sjögren's syndrome. 188
Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients 187
EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. 186
Differentiation between early rheumatoid and early psoriatic arthritis by the ultrasonographic study of the synovio-entheseal complex of the small joints of the hands 184
Terapia dell'artrite reumatoide con immunoglobuline per via endovenosa ad alte dosi: esperienza clinica e revisione della letteratura 184
Gitelman syndrome disclosed by calcium pyrophosphate deposition disease: Early diagnosis by ultrasonographic study 183
AB0695 Anti-prothrombin/phosphatidyl-serine complex autoantibodies in antiphospholipid syndrome: Preliminary data using a new ELISA method 179
Validation of the classification criteria for cryoglobulinaemic vasculitis. 178
Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. 178
A randomized controlled trial of rituximab for treatment of severe cryoglobulinemic vasculitis. 177
2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts 176
A randomized, controlled, multicenter phase iii study of the efficacy and safety of rituximab (rtx) monotherapy versus the best available treatment (bat) in patients with mixed cryoglobulinemia syndrome (MC) Ann Rheum Dis 2010;69(Suppl3):93 174
Pachydermodactyly: The role of ultrasonography and dermoscopy for diagnosis 173
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 170
Acetaminophen-induced liver injury in a woman with febrile flare of systemic lupus erythematosus 170
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 169
B-cell clonality and infection with Helicobacter pylori: implications for development of gastric lymphoma 169
B cell clonality in gastric lymphoid tissues of patients with Sjogren's syndrome 168
Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study 168
Medical data quality assessment: On the development of an automated framework for medical data curation 168
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients 167
The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis 167
B-cell lymphomas associated with HCV infection 167
Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study 165
HCV-related liver and lymphoproliferative diseases: Association with polymorphisms of IL28B and TLR2 165
Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. 165
Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren's syndrome 164
BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands 160
A B-cell activating factor receptor (BAFF-R) His159Tyr mutation in Sjögren's Syndrome related lymphoproliferation 160
Misoprostol-induced urinary incontinence 158
EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. 158
Use of teriparatide in osteoporosis due to active rheumatic diseases 157
Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study. 157
Efficacy of intravenous cyclosporine in a case of cytophagic histiocytic panniculitis complicated by haemophagocytic syndrome after visceral leishmania infection 157
Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. 156
Hepatitis C virus, non-Hodgkin's lymphomas and hepatocellular carcinoma 156
Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome 155
Cryoglobulinaemia related to Sjogren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. 154
SALIVARY GLAND ECHOGRAPHY IN PRIMARY AND SECONDARY SJOGREN'S SYNDROME 154
Emerging drugs for primary Sjögren’s syndrome 154
Plasmocitoma micromolecolare osteosclerotico 153
Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. 152
Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. 151
A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (rtx) monotherapy versus the best available treatment (bat) in patients with mixed cryoglobulinemia syndrome (MC) 151
Rituximab for the treatment of type II mixed cryoglobulinemia. 150
Strontium ranelate and femural fracture healing during rheumatoid arthritis and osteoporosis 150
BLyS and April serum levels in patients with autoimmune thyroid diseases. 150
Cost-effectiveness analysis of two Rituximab retreatment regimens for longstanding rheumatoid arthritis. 150
Knuckle pads mimic early psoriatic arthritis 150
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. 150
Patient-reported impact of spondyloarthritis on work disability and working life: The ATLANTIS survey 149
Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides. 148
Low frequency of bcl-2 rearrangement in HCV-associated non-Hodgkin's lymphoma tissue 148
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis 148
Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection 148
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 147
Development of the ClinESSDAI: A clinical score without biological domain. A tool for biological studies 147
Retrospective analysis of the usefulness of a protocol with high-dose methotrexate in polymyalgia rheumatica: Results of a single-center cohort of 100 patients 147
B-cell clonality in gastric mucosa of patients with Sjögren's syndrome and connective tissue diseases: relationship with Helicobacter pylori, EBV and human herpesvirus-6 (HHV-6) infections. 145
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 145
Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). 144
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. 144
Role e of oral cyclophosphamide in the treatment of giant cell arteritis 143
BLyS Role in the Diagnosis and Prognosis of Neuroendocrine Tumors: Preliminary Results. 143
Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution 143
Ciclosporina e tacrolimus nella miosite da corpi inclusi: efficacia clinica, sicurezza e risparmio nell'uso dei corticosteroidi 142
Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. 142
Treatment of rheumatoid arthritis with rituximab: an update and possible indications. 142
L. Quartuccio, M. Fabris, M. Maset, E. Pontarini, A. Zabotti, S. De Vita Bone marrow b-cell expansion in mixed cryoglobulinemia: association with nephritis and response to rituximab 141
Mycophenolic Acid AUC estimation in patients with lupus nephritis using an algorithm validated in an heart transplanted population 141
Dermoscopy of nail fold and elbow in the differential diagnosis of early psoriatic arthritis sine psoriasis and early rheumatoid arthritis 141
B cell driving cytokines in eraly rheumatoid arthritis. Assessment of possibile clonal expansions during treatment with cyclosporin A. Arthritis and Rheumatism 1996; 39 (Suppl.): S26. 140
General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus 140
Rituximab monotherapy, rather than rituximab plus antiviral drugs, for initial treatment of severe hepatitis C virus-associated mixed cryoglobulinemia syndrome: comment on the article by Terrier et al 140
The Detection of Anti-adalimumab Antibodies in a Series of Inflammatory Polyarthritis: three ELISA Methods Compared 140
HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC) 140
Frequent detection of human herpesvirus 6 DNA in HIV-associated lymphadenopathy. 139
B-lymphocyte stimulator and a proliferation-inducing ligand serum levels in IgA-deficient patients with and without celiac disease 139
Combinad therapy with cyclobenzaprina and ipuprofen in primary fibromialgia sindrome 139
Subtypes of Epstein-Barr virus in HIV-1-associated and HIV-1-unrelated Hodgkin's disease cases. 139
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care 139
Combination therapy with cyclosporin-A plus methotrexate in adult Still’s disease: efficacy and safety. . 138
Multifocal ischemic necrosis of bone in scleroderma. 138
Dermoscopy in the differential diagnosis between malar rash of systemic lupus erythematosus and erythematotelangiectatic rosacea: an observational study 138
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors 138
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 137
Classification of cryoglobulinemic vasculitis 136
Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. 136
Treatment of giant cell arteritis with cyclophosphamide pulses 136
B-CELL CLONAL EXPANSION IN GASTRIC BIOPSIES OF PATIENTS WITH DYSPEPSIA AND AUTOIMMUNE-DISEASES - EFFECT OF HELICOBACTER-PYLORI ERADICATION 136
Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis 136
Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus 136
A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome. 135
Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis: reply 135
Rarity of microsatellite genomic instability in B-cell non-Hodgkin's lymphomas in hepatitis C virus-infected patients 135
Clinical differences between ANA/anti-ENA positive or negative primary Sjögren's syndrome 134
Totale 15.608
Categoria #
all - tutte 194.527
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 194.527


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.041 0 0 0 0 0 0 0 0 0 139 663 239
2021/20223.523 89 403 162 380 108 105 156 232 48 532 673 635
2022/20233.839 515 167 69 427 393 1.043 33 287 574 56 114 161
2023/20241.238 179 120 47 26 223 190 51 93 168 67 24 50
2024/20258.740 202 606 300 238 391 413 451 581 931 765 1.402 2.460
2025/202613.030 1.100 1.468 1.293 1.524 2.183 1.273 1.653 553 1.023 960 0 0
Totale 52.737